Dr. Donna R Gibbons Markey, MD Otolaryngology - Otolaryngic Allergy Medicare: Not Enrolled in Medicare Practice Location: 5685 Arroyo Luis Dr, Bulverde, TX 78163 Phone: 210-421-3900 Fax: 210-767-9820 |
News Archive
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Immune Pharmaceuticals, Inc. announced today that its Chief Executive Officer, Dr. Daniel Teper, has established a stock trading plan with respect to the purchases of up to an aggregate of $250,000 of shares of Immune common stock in accordance with Rule 10b5-1 under the Exchange Act and other applicable federal securities laws and regulations adopted by the Securities and Exchange Commission.
Artemisinin-based combination therapies (ACTs) are the currently recommended drugs for treating malaria. However, they are expensive, which limits their affordability. This means that people with malaria are likely to buy cheaper, less effective antimalarials such as chloroquine and sulphadoxine-pyrimethamine; or to simply buy painkillers and antipyretics.
Canadian researchers at The Ottawa Hospital, the University of Ottawa, the Bruyère Research Institute and ICES have built and validated an online calculator that empowers individuals 55 and over to better understand the health of their brain and how they can reduce their risk of being diagnosed with dementia in the next five years.
The American Association of Critical-Care Nurses will present the ICU Design Citation to the newborn and infant critical care unit (NICCU) at Children's Hospital Los Angeles during the 2014 National Teaching Institute & Critical Care Exposition, Denver, May 17-22.
› Verified 4 days ago